Lipid signatures of West Nile virus infection unveil alterations of sphingolipid metabolism providing novel biomarkers

Emerg Microbes Infect. 2023 Dec;12(2):2231556. doi: 10.1080/22221751.2023.2231556.

Abstract

West Nile virus (WNV) is a neurotropic flavivirus transmitted by the bites of infected mosquitoes. Severe forms of West Nile disease (WND) can curse with meningitis, encephalitis or acute flaccid paralysis. A better understanding of the physiopathology associated with disease progression is mandatory to find biomarkers and effective therapies. In this scenario, blood derivatives (plasma and serum) constitute the more commonly used biofluids due to its ease of collection and high value for diagnostic purposes. Therefore, the potential impact of this virus in the circulating lipidome was addressed combining the analysis of samples from experimentally infected mice and naturally WND patients. Our results unveil dynamic alterations in the lipidome that define specific metabolic fingerprints of different infection stages. Concomitant with neuroinvasion in mice, the lipid landscape was dominated by a metabolic reprograming that resulted in significant elevations of circulating sphingolipids (ceramides, dihydroceramides, and dihydrosphingomyelins), phosphatidylethanolamines and triacylglycerols. Remarkably, patients suffering from WND also displayed an elevation of ceramides, dihydroceramides, lactosylceramides, and monoacylglycerols in their sera. The dysregulation of sphingolipid metabolism by WNV may provide new therapeutic opportunities and supports the potential of certain lipids as novel peripheral biomarkers of WND progression.

Keywords: West Nile virus; biomarker; lipid; patient; viral infection.

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Ceramides / metabolism
  • Ceramides / therapeutic use
  • Mice
  • Sphingolipids / metabolism
  • Sphingolipids / therapeutic use
  • West Nile Fever*
  • West Nile virus* / genetics

Substances

  • Sphingolipids
  • dihydroceramide
  • Ceramides
  • Biomarkers

Grants and funding

This study was supported by Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 under grant PID2019-105117RR-C21 (to MAMA) and by the European Commission – NextGenerationEU through CSIC's Global Health Platform (PTI Salud Global). PMC was supported by a FPI fellowship from AEI/10.13039/501100011033 under grant PRE2020-093374. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.